Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07407803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Recruitment opened Start date changed from estimate of Feb 2026 to Mar 31, 2026 · Site details revised at 29 of 29 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Feb 2026 to Mar 31, 2026
    • Site details revised at 29 of 29 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.
Trial Details
NCT Number NCT07407803
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Plexiform Neurofibroma
Enrollment 177 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov